| scholarly article | Q13442814 |
| P356 | DOI | 10.18553/JMCP.2008.14.6.523 |
| P8608 | Fatcat ID | release_bq32kyktcbg7bgi7stfwhunqey |
| P698 | PubMed publication ID | 18693776 |
| P2093 | author name string | Alan H Heaton | |
| Jeremy A Schafer | |||
| Patrick P Gleason | |||
| Catherine I Starner | |||
| P433 | issue | 6 | |
| P921 | main subject | (RS)-rosiglitazone | Q424771 |
| P304 | page(s) | 523-531 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Journal of Managed Care Pharmacy | Q15757065 |
| P1476 | title | Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | |
| P478 | volume | 14 |
| Q36766202 | A review of the hypoglycemic effects of five commonly used herbal food supplements |
| Q34105156 | Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review |
| Q40525160 | Association of Attorney Advertising and FDA Action with Prescription Claims: A Time Series Segmented Regression Analysis |
| Q50155852 | Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? |
| Q43265650 | Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain |
| Q40649706 | Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. |
| Q39489588 | Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study |
| Q30359158 | Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs |
| Q37545937 | How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? |
| Q35928690 | Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review |
| Q37957629 | Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice. |
| Q41807349 | Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. |
| Q38000336 | Impact of safety-related regulatory action on clinical practice: a systematic review. |
| Q64272880 | Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes |
| Q37185836 | Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study |
| Q36078772 | Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione |
| Q37276717 | Management of progressive type 2 diabetes: role of insulin therapy |
| Q47653552 | Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations |
| Q37133799 | Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study |
| Q38195003 | Methodological gaps in the assessment of risk minimization interventions: a systematic review |
| Q47987919 | Non-health Care Facility Medication Errors Associated with Hormones and Hormone Antagonists in the United States |
| Q38807857 | Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness |
| Q39029023 | PPARs and nonalcoholic fatty liver disease |
| Q37298063 | Peroxisome proliferator-activated receptor-gamma agonist improves skeletal muscle insulin signaling in the pregestational intrauterine growth-restricted rat offspring |
| Q83509399 | Polypharmacy associated with medical tourism: a critique on drug therapy |
| Q43703608 | Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. |
| Q36620262 | Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone |
| Q42876103 | Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan |
| Q34623567 | Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010. |
| Q24604853 | State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning |
| Q34389980 | Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS) |
| Q35183125 | Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management |
| Q38974109 | The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells |
| Q37738725 | Update on the safety of thiazolidinediones |
| Q35141084 | Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. |
Search more.